15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$9M | — | — | -$8M | — | $7M |
| 2024 | — | -$18M | — | — | -$16M | — | $10M |
| 2023 | — | -$18M | — | — | -$15M | — | $26M |
| 2022 | — | -$39M | — | — | -$22M | — | $37M |
| 2021 | — | -$14M | — | — | -$13M | — | $59M |
| 2020 | $2M | -$10M | 0.0% | -476.0% | -$10M | — | $33M |
| 2019 | $7M | -$48M | 0.0% | -737.4% | -$2M | — | $7M |
| 2018 | — | -$49M | — | — | -$8M | — | — |
| 2017 | — | -$613000 | — | — | -$7M | — | $748000 |
| 2016 | — | -$75M | — | — | -$15M | — | $4M |
| 2015 | — | -$50M | — | — | -$11M | $50M | $9M |
| 2014 | — | -$99000 | — | — | -$6M | $65M | $4M |
| 2014 | — | -$13M | — | — | — | — | $3M |
| 2013 | — | -$4M | — | — | -$4M | — | $1M |
| 2012 | — | -$8M | — | — | -$2M | — | $5M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $225000 | -$2M | 0.0% | -1047.1% | — | — | — |
| Dec '25 | — | -$2M | — | — | -$2M | — | $7M |
| Sep '25 | — | -$2M | — | — | — | — | — |
| Jun '25 | — | -$2M | — | — | — | — | — |
| Mar '25 | — | -$2M | — | — | — | — | — |
| Dec '24 | — | -$3M | — | — | -$3M | — | $10M |
| Sep '24 | — | -$5M | — | — | -$5M | — | — |
| Jun '24 | — | -$5M | — | — | -$4M | — | $18M |
| Mar '24 | — | -$4M | — | — | -$5M | — | $22M |
| Dec '23 | — | -$4M | — | — | -$3M | — | $26M |
| Sep '23 | — | -$4M | — | — | -$3M | — | $30M |
| Jun '23 | — | -$4M | — | — | -$6M | — | $32M |
| Mar '23 | — | -$5M | — | — | -$3M | — | $34M |
| Dec '22 | — | -$5M | — | — | -$5M | — | $37M |
| Sep '22 | — | -$6M | — | — | — | — | $42M |
| Jun '22 | — | -$24M | — | — | — | — | $51M |
| Mar '22 | — | -$4M | — | — | — | — | $55M |
| Dec '21 | — | -$4M | — | — | -$3M | — | $59M |
| Sep '21 | — | -$4M | — | — | -$5M | — | $62M |
| Jun '21 | — | -$4M | — | — | -$3M | — | $67M |
Over the past 5 years, Cocrystal Pharma, Inc.'s revenue has declined 69.3% per year. These are computed facts, not advice.
As of FY2025, Cocrystal Pharma, Inc. reported — of total debt against $7M of cash; operating income covered interest expense 67×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.